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Although coronary blood flow is closely controlled to meet 
myocardial metabolic demands under normal conditions. the 
mechanism. or mechanisms. responsible for metabolic COT- 
oaary vasoregulation remains uncertain (I). Adenosine has 
been widely investigated as a potential regulator ofcoronary 
tbw. Theophylline and other methylxanthines are known to 
antagonize adenosine-induced vasodilation in the coronary 
circulation of animals (2.3) and in the human forearm 14). 
Numerous animal shuJies have examined coronary Row 
responses after adenosine antagonism with methylxdnthines 
or destruction of adenosine by adenosine deaminsse, with 
inconsistent results. Some studies demonstrate that adeno- 
siae plays a significant role in regulation of coronary Row 
daring reactive hyperemia (5.6). pacing-induced hyperemia 
(7,8), inouopic stimulation wifh dobutamine (9) and behav- 
iorally induced coronary Row increases (IO). In contrast, 
other studies indicate no change in basal myocardial blood 
Row (I 1.12). metabolic regulation (13). coronary vasodila- 
fion during exercise (14) and coroaary autoregulation (15) 
after pharmacologic reduction of adenosine activity. 
Few data are available with regard to the role of adeno- 
sine in coronary vasoregulation in humans. Also. the etlicacy 
of aminophylline in inhibiting adenosine-induced coronary 
vasodilation in humans is unknown. Accordingly, the pur- 
p~sc of this study was to assea~ the importance afadenosine 
in mediaring the coronary vasodilation that occurs with atrial 
pacing stress. AminophyUine was used to produce pharma- 
cologic antagonism of adenosine-induced coronary vasodi- 
lation. and the exted of this e5ect was assessed usinggraded 
intracoronary adenosine infusions before and after amino- 
phylline. 
Methods 
Patients undergoing elective coronary aneriography for the 
evaluation of chest pain were considered for study if auAiog- 
raphy revealed a nonstenotic coronary artery that was 
anatomically suitable for placement of a coronary Doppler 
catheter and there was no evidence of left ventricular 
dysfunction. The research protocol was approved by the 
University of Iowa Institutional Review Board, and written 
informed consent was obtained from each patier.t before 
cardiac catheterization. 
Coronary Aow velocity measurement. Changes in corn-- 
nary blood flow were assessed using intracoronary Doppler 
catheter measurement of coronary Row velocity according to 
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the method of Wilson et al. (16). A 7F or 8F coronary 
angioplasty guide catheter was positioned at the coronary 
ostium. and a 0.014-i”. coronary angioplasty guide wire was 
advanced into the coro”ary artery to be studied. A 3F 
20.MHz coronary Doppler catheter with a” infusion lumen 
at its tin tNuMed Inc.) was advanced over the nuide wire 
into the proximal vessel and positioned to obtain a high 
quality phasic signal of blood flow velocity. Tlte ptdsed 
Doppler meter (Bioenghteering Department, University of 
Iowa Hospitals and Clinics) was range gated to maximize the 
amplitude of the mean coronary Mood Row velocity signal. 
Phasic and mean coronary blood flow velocity BtHz shift). 
mea” arterial pressure (mm Hg) obtained from the guidhtg 
catheter, heart rate tbeatsJmi”f and surface ekctrocardic- 
gram were continuously recorded on a multichannel re- 
corder. Alterations in coronary blood flow velocity were 
expressed as percent change frmn the rest value. A” index of 
change in coronary vascular resistance was also calculated 
as the quotient of mea” aortic pressure (mm Hgvblood Row 
velocity (kHz shift) after an intervention and mea” aortic 
pressureiblood Row velocity a1 control conditions. 
Es&m&al pmtoeol. Subjects were bmught to the car- 
diac catheterization laboratory in a fasting state. Prescribed 
medications were continued on the day of the research 
study. Diaaepam (5-10 mg intravenously or orally) was give” 
for sedation. No patient received atropine pnmedication. 
The study was performed during intravenous infuaitm of 
nitroglycerin at 8 “gamin to prevent catheter-induced core- 
nary rutety spasm and to avoid changes in coronary artery 
caliber that would influence the relation between clutngcs in 
coronary Row velocity and coronary blood flow. No patient 
received medications containing methylxanthines or dipyr- 
idamole. Beverages containing methylxanthims were with- 
held for at least I2 h before the procedure. 
@XI of aminophylline on udenosinc-induced coronary 
vosodilukm The effect of acute administration of intrave- 
nous aminophylline on the coronary vasodilator actions of 
intracoronary adenosine was studied in two female and five 
male patients with a mean (*SD) age of 58 2 I2 years. 
Coronary flow velocity was measured in the letI anterior 
descending coronary artery in all patients. Single-vessel 
coronary artery disease (diameter stenosis >50%) was 
present in one patient, and minor lumen irregularities were 
seen in three patients. Medications included calcium channel 
blocking agents in four patients. No patients were receiving 
beta-adrenergic blocking agents. 
A 6F bipolar pacemaker was positioned at tlte bii tight 
atrium, and atrial pacing was performed at I5 beats/min 
above the rest rate thmughout the protocol to prevent 
changes in coronary Row related to aminophylline-induced 
increases in heart rate. Adenosine (Adenocard, Fujisnwa 
Pharmaceutical Company) in normal saline solution was 
infused through the infusion lumen of the intracoronaty 
Doppler catheter at IO and 40 Icglmin for 2 min each. All . .^. _ ._. 
variables were allowed to return to baseline between infu- 
sions. AminophyBiae (Abbott laboratories) was the” in- 
fused intravenously at the dose of 6 me&a over 10 min. The 
adetmsme ittfusioas were repeated, and blood was drawn for 
measurement of serum tbwpbylline level 5 to 10 min after 
completion of the aminophyllhte infusion. 
E&I ofominophylfine on metabolically mediored core- 
nary varodifarion. The e&i of adenosine antagonism with 
aminopbyBine on tbe coronary blood flow response to rapid 
atrial pacing stress was assessed in I5 patients. In three 
patients, marked changes in the mean flow velocity signal 
were obsesved after aminopayninc edtiistmtimt. s”ggest- 
ing movement of the Doppler catheter during the protocol; 
these studies were discorded. In the rmnahtbrg six female 
and six male patients (mean age 54 + II years), single-vessel 
coronary artery disease (diameter stewsis 250%) was 
present in one. and minor Innten irreg&“itk~ were see” in 
five. Coronary Sow velocity was measured in lhe left ante- 
rior descending coronary artery in nine patients. in the left 
cbcumBex CnmnalY artery in two patients and in the left 
ntai” cu~onary a&y in-one f&&t. Medications take” 
included beta-blockers in one patient and cakium channel 
blockers in six patients. TM? iavaeomaary adenosine proto 
MI was also performed in two of these patients. 
A 6F bipolar pwmaker was w at the bii right 
atrium. snd atria1 pacing was performed at I5 beat&i” 
related to aminopbylline&hmed inc&es in heart- rate. 
Myoeardii tnetabulii demands were increased by gradually 
incrcaaing tba beart rate over 2 mitt with atrial pacing to the 
highnt rate attabmbk withoot atriovmttticufar b&L; this 
m,e was maintained for 2 “Ii”. After a 5mi” recovery 
period, rathphyUine was infused intravenoluly at the dose 
of6mrlkPbodvweiphtovalOmia.‘IhersDidatriplaaeian 
protocol was r&&d. and blood was drawn for n&t& 
ment of the sentm tbeopbyBine kvel 5 IO IO mitt aBcr 
completion of the aminopbylline infusii. 
Data asalyak Group data in the text are presented as 
mean value f SD. Changes in study variables wetu com- 
pared using the Student I test or two-way analysis of 
variance for repeated measures, with assessmenl of inter- 
gm”p diiere”ces using the SchctTC F test. Differences were 
considered signii~ at the p d 0.05 level. 
RCSURS 
BReclofamknphyuhKou-kldoccdmmMry 
vasodllatlon. Sysfemic hemodymvnic status. Throughout 
the study heart rate was maintained at 89 t IO beatslmin by 
serial pacing. Mean arterial pressure averaged 109 + 
II mm Hg under control conditions and was unchanged 
during the intracoronary adenosine b&ions nnd the hut-a- 
venous aminophylline infusion (Table I). Alter aminophyl- 
tine infusion, the serum tbeophylline level averaged 10.3 + 
.^ ,. 
auenosme mtu~ton~ were pertormed at a volume mtuston 
rate of 3 mllmin with a piston pump, and hemodynamic t.s ng7mt. 
Coronary blond&w velocity. intmcomnar, infusion of 
adenosine at 10 &-min before &inophylline administration 
resulted in an R4 ? 48% increase in cornnarv blood Row 
velocity (Fig. I). Adenosine infusion at 40 p&in resulted in 
an increase in camnary flow velocity of I30 f 35%. The 
coronary bled Row response tn adenosine was markedly 
blunted by aminophylline. After aminophylline adminism- 
lion. the adenosine-induced increase in coronary S&d Row 
was attenuated IO 21 2 31% (p < O.GuI vs. control values) 
and 59 -C 51% (p C 0.001 vs. control values) for infusions at 
IO and 40 &tin, respectively (Fig. I). 
Coronary vascular resistance index. Intncoronary infu- 
sion of adenosine under cantrnl conditions resulted in B 
decrease in corunaq vascular reeFistauce index to 0.57 z 
0.1 I during the IC-cls/min infusion and 0.45 + 0.1 during the 
4O&min infusion. AtIer aminophylline administraGan. the 
adenosine-induced decrease in coronary wcular resistance 
index was attenuaIed to 0.86 + 0.1s IO < 0.01 vs. control 
vahtes) and 0.67 k Ct.17 (p < 0.01 vs. control values) for 
infusions a1 10 awl 40 /&mitt. respectively. Thus, the 
cnrmtary vaaudilator effect of intrxomnary adenosine infu- 
sions producing submaximal coronw; hgrremia was sub 
stantially reduced by aminophylline. 
E&Ctd~~lllet%~ymediplrd~ 
vmudiWm. Systemic hcmodynomic smnts. Control and 
peak paced heart rater (78 + 8 and I23 + 9 beat&in. 
respectively) were identical before and atIer aminophylline 
administtatiott. Aminophyiline infusinn resulted in a decrease 
in mean arterial pressure front IO2 ? I2 to 94 t 9 mm Hg 
(p 4 0.05) (Fii. 2). During paced tachycardia. mean arterial 
F@m I. Effect ofintravenous aminophylline on the coronary blood 
Row velocity response to inwacomnary infusions of adenosine. Eata 
are areup mean vatue f SD. ‘p < o.Wt versus canfml condhions. 
cantret PS.9 n 
F@re 2. Effect of mtravenous aminophylline (AM) on wan arte- 
nrd pressure nnd coronary btwd Row v&city during increases in 
myocardial merobolic demand resulting from paced tachyeardia 
IPACEI. During conlml pduds. heat1 rate was mGuained at 
IS bearsimin above [hi: initial rest rale. Cnrmq blood WV velccily 
is expressed as percent change from the inirkl cLnfmi flow v&city. 
Dam xe group menn value ? SD. ‘p < 0.0s versus conrml 
condillons and lilpid ~trial pacing. Tp < 0.01 versus control condi- 
tums and at?er aminophylline. 
pressure was unchanged from the respective control vnlues 
(Fig. 2). After aminophylline infusion, the serum theophyl- 
line level averaged 12.1 -C 3.0 @ml. 
Corcna~ blood ,t%ne wlociry. Coronary blood Row ve- 
locity increased by 26 i 16% during paced tachycardia 
before aminophylline administration 61 < 0.011 (Fig. 2). 
Control flow velocity was not significantly a&ted by amin- 
ophylline (-5 t 9% change front the initial control flow 
velocity). During paced tachycacdia after aminophylline 
administration. cc&mary flow velocity increased by 23 * 
10% over the aminoohylline control values (I, < 0.01). which . 
was similar to that observed before aminophylline adminis- 
tration. Thos. the increase in flow velocity during pacing 
tachycardia was not attenuated by sdanosine antagonism 
with aminophylline. 
Coronury vnsc~lar resishwrce indetr. Aminophylline had 
no effect on the cornnary vascular resistance index during 
paced tachycardia (0.80 2 0.10 before, 0.82 + 0.06 after 
aminophylline) (Fig. 3). 
Discussion 
This study demonstrates that coronary blood Row responses 
to intracoronary infusions of adenosine. producing submax- 
imal vasadilalion, are substantially reduced by administra- 
tion of intravenous aminophylline in humans. This effect is 
consistent with antagonism by theophylline of adenosine 
receptors that mediate coronary vasodilation and was ob- 
served with a dose of aminophylline commonly used in 
clinical practice. Although aminophylline markedly attenu- 
ated the coronary vasodilator effect of adenosine, it did not 
influence coronary vasodilatian related to increased myocar- 
dial metabolic demands produced by rapid atrial pacing 
stress. These dm suggest that r&wine does not play an 
imwrllt role in the reaulation of coronarv blood flow in 
re&nse to aerial pa&in humans. . 
B&cl of amlnopbyllhle ml adenoshle coronuy vasadllr- 
Uan. Melhylxanthines are known to sekctivcly inhibit 
adenosine-induced vasodilation in the coronary circulation 
of animals (23). In humans, aminophylline and calfeine 
attenuate adenosine-induced incrcases~in forearm blood Row 
(4.17) and systemic hemodvnamic chanaes 118.19). Tha 
effect of mclhylxanthincs oa adenosine-iiduced coronary 
vasodilation in humans has been assessed indirectly by 
demonstration of the elimination of dipytidamokbuluced 
coronary sinus flow increases by aminophyllinc (20) and 
abnormalities in myocardial gcrfusion scans by theophylline 
(21). The present study is the first lo directly dcmbnstrate 
attenuation of the coronary vasodilalor elfect of adenosine 
by methylxanthines in humans. 
The adenosbtc hypelhuls. The close association between 
myocardiai oxygen demand and perfusion suggests that 
products of myocardiai metabolism act as messengers in the 
control of coronary blood flow. Although several potential 
chemical regulators have been proposed and studied, the 
mechanisms of metabolic coronary vasoregulation remain 
uncertain (I). A mk for adenoshle in the control of coronary 
Row was suggested by Beme (22), and studies in animals 
demonstrate that adenosine fulfills several criteria for this 
purpose. Adenosine elicits coronary vasodilation at very low 
concentrations (23). It is rcleascd from the heart during 
inolropic stimulation (24). exercise 12.5) and conditions in 
which myocardial oxygen supply is insuUicien1 lo meet 
demands. such as hypoxia (22). However, studier using 
pharmacologic reduction in adenosine activity lo attenuate 
coronary vasomolor responses have been inconclusive (26). 
A number of studies SUPWR 1he”adenosine hvnothesis.” In . . 
anesthetized dogs, intt&cnous aminophyUine resulted in a 
reduction in the increment in coronary flow during atrial 
pacing and an increase in the transcardiac anwiovenous 
oxygen di@erence (7.8). Coronary vasedilation in response 
lo inolropic stimulation wi!h dobutamine was blunted by 
Bp-sutfophenyhheophylline in anesthetized dogs (9). Reac- 
tive hypercmia after brief cornnary occlusion was reduced 
by intracomnary adenosine deaminase or thcophylline in 
anesthetized dogs (27) and by int~venous aminophyliine in 
conscious dogs (6). increases in coronary blood Row related 
to aversive stress were attenuated by inu-avenous amino- 
phylline in conscious dogs (10). 
The rcsuhs oiotbx studies appear to bc inconsistent with 
the adenosine hynobesis. Inttacoronary adceosine deami- 
twe pmduced &or or no changes k basal myocardial 
blood Row in sedated pigs and anesthetized dogs (llJ2). No 
change in myocardial reactive hypenmia was observed after 
intravenous aminophyliine (26). AminophyUine did not rc- 
duce limctional hypcamia resulting from intracomnary nor- 
epinephrine infusion in anesthetized dogs (29). and neither 
the potent adenosine antagonist I-phenyltheophyiiinc nor 
adenosine deaminase reduced hyparemia in exercising dogs 
114). Coronary autoregulation was unaffected by intracoro- 
nary adenosine de&t&e (15) and by topical adenosine 
deaminase and WmnyltheophylUne (36) in anesthetized 
dogs. It is fily that dilferent mechanisms are involved in 
coronary blood flow regulation during the multitude of Row 
perlurbalionr used in studies of the adenosine hypothesis. 
and some mechanisms may not be pertinent lo the regulation 
of coronary blood flow in response lo increased oxygen 
demand. 
Information with regard to the mk of adcnosinc in the 
regulation of coronary blood flow in humans is liilcd. 
Bdhmd et al. (20) assessed the effect of intravenous amino. 
phylline on comnary hemodynamic status during supine 
cycling in nomtal subjects. ABer aminophylline admhtistra- 
lion, cornnary vascular resistance sod myocmdii oxygen 
extraction during exercise were hscreascd compared with 
control vahteo, although coronary sinus thcrmcdilulion iIow 
was not chaagcd signilkantly. 
AdeWdWrddbordmd(kkmueavWUJ-M 
lion. Several studies have reported that aminophyUine pos- 
sesses sign&ant antianginal activity in patients with ob- 
structive coronary artery disease 131.32) and syndrome X 
133). This antianginai etrect has been attributed to adenosim 
aceplor blockade, with a resultant decrease in adenoshte- 
mediated ischcmic pain, or to improvcmcnt in coronary 
blood flow lo ischemic regions. A role for adenosinc in the 
development of anghtal paht is suggested by several obser- 
vations. Angina-like pain occurs during adcnosinc intravc- 
now infusion in healthy subjects 1.34). as well as durina 
inlracoronary infusion in patients with coronary artery di; 
ease 135). and anginal pain produced by inlracoronary aden- 
osine is reduced by intravenous aminophylline (IS). Patients 
in the present study were asymptomatic during inlracoro. 
nary adenosine infusions at doses below those needed IO 
could lead-to improved blood flow to ischemic areas by 
blunting metabolic vasodilation to normally perfused myo- 
cardial regions. In our study, aminophylline had no effect on 
metabolic vasodilation to a nonischemrc vascular bed. How- 
ever, we cannot exclude the possibility that adenosine 
antagonism caused favorable transmural redistribution of 
coronary blood flow that could not be detected by DOQQiCr 
catheter assessment of &anal Row. 
Liitiorw. In the present study, changes in coronary 
blood ROW were assessed using intracoronary Doppler cath- 
eter mea~~retnen!~ of coronary Rcw velocity rather than 
absolute measurements of coronary blood Bow. However. 
extensive animal studies validating the coronary Doppler 
catheter design used in this study have been published (16). 
The records of three patients were discarded because of 
marked alterations in caronary flow velocity (increased m 
two patients, decreased in one patientJ. suggesting move- 
ment of the Doppler catheter within the coronary artery. The 
results of this study are unchanged by inclusion of these 
patients. If all IS patients had been analyzed. the increase in 
cormtary Row velocity with paced tachycnrdin would have 
been 26 + 14% under control conditions and 24 + 10% after 
amirmphylline administration (p = NSJ. 
trons are plausible. Several potential limitations relate to the 
use of aminophylline. In the present study, aminophy8ine 
was demonstrated t” attenuate adenosine-induced coronary 
Row increases that were greater in magnitude thas the 
vasodilation occurring with pacing. Because aminophylline 
is thought to be a competitive antagonist of adenosine 
receptors. equivalent attenuation of smaller degrees of va- 
sodilation due to adenosine would be expected. but this was 
not demonrtnted swciticaliv in this study. It is possible that 
the adeuosine recebtors on vascular smooth muscle, rather 
than endothelial cell adenosine receptors, are important in 
cor”narv blood how regulation. Whether aminaphylline. 
which ib a relatively weak antagonist of aden”sine&hrced 
vasodilauon compared with agents available for use in 
animal studies, produces blockade of vascular smooth mus- 
cle odenosine receptors in humans is uncertain. Adenosine 
production dunng increased oxygen demand may be en- 
hanced by ‘.tdecos?re antagonists (37). Increased adenorine 
production may lar,!y overcome competitive receptor 
blockade nnd maintain functional hrperemia near control 
A nitroglycerin low dose (8 rcgimin) intravenous infusion 
was used during coronary blood Row velocity measurement 
to prevent catheter-induced coronary artery spasm and to 
avoid changes in coronary artery caliber that would intlu- 
ewe the relation between changes in coronary llow velocity 
and cornnary blood flow. It is possible that the nitroglycerin 
infusion influenced the results of the study. However, our 
laboratory has demonstrated that nittnglycerin in much 
larger doses has minimal sustained etfects on coronary blood 
tlow f86.1. Furthermore. because the nitroalvcerin infusion 
co&& throughout the study. any eff& on coronnry 
blood flow responses would be present both at control 
conditions and after aminophylline infusion. The antianghud 
medications that mm” ptients received might have intlu- 
enced tha initial hemodynamic response to atrial pacing. 
However, it seems unlikely that these medications altered 
the effect of adcnosine antagonism on the coronary Row 
nsponse lo atrial pacing, as they have a” known activity at 
adcnosine receptors, and medication effects were present 
both at contml conditions aml alter nminophyllinc infusion. 
levels. 
It is possible that several mediators may interxt in the 
reculation of coronurv blood flow, and other mediators ow 
compenrste for loss of adenosine activity to maintain phyi- 
iologic responses. 
Finallv. the “acme orotocol used in this studv oroducsd a 
modest &crease in ~&onaty blood flow. Thtswsmall inittal 
response makes demonstration of a reduction in the re- 
sponse by an uuervention more difficult. Adenosine may 
play a greater role in metabolic coronary vasodilation at 
higher levels of myocardial oxygen demand than were 
achieved in this study. 
Allhough Row responses were measured in a nonstenotic 
eomnary artery in all patients. it is uncertain whether the 
interrogated vessel was physiologically normal. It is possible 
that abnotmalities in cndothelial function were present in our 
study group, given the age of the patients and the presence of 
risk factors for coronary artery disease and angiographically 
evident coronary irregularities in many of the patients. 
Mechanisms of control of coronary blood Row during in- 
creased myocardial oxygen demand may differ in nomtal 
patients and in those with nonobstructive coronary athero- 
sclerosis. 
ltttntvenous aminoohvlline markedlv attenuated the cor- . . 
onary vaandilator effect of exogenously administered aden- 
asine but did not influence pacing-induced functional hy- 
peremia in this study. Although these findings provide 
evidence against the adenosine hypothesis, other explana- 
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